In vivo fasted-state bioequivalence study of Diltiazem 60 mg tablet
Design
The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy volunteers will participate randomly in the study as two twelve-person study groups. Each volunteer will receive a single dose of drug in two periods. In one period the test formulation and in another period the reference formulation. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.
Settings and conduct
After oral administration of 60 mg tablet to volunteer, the blood samples will be collected in predetermined time intervals up to 12 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. The concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences.
Participants/Inclusion and exclusion criteria
Inclusion criteria: General Health (in terms of Liver, Heart and Kidney); age: 18-59 years old. Exclusion criteria: smoking; history of cardiovascular, liver and kidney disease; pregnancy; alcohol and drug addiction; history of drug allergy.
Intervention groups
Intervention group will receive a single oral dose of test drug product (Diltiazem 60 mg tablet manufactured by MehrDarou, Iran) and Control group will receive a single dose of reference drug product (Diltiazem 60 mg tablet manufactured by Sanofi). Blood samples will be taken for 12 hours at the mentioned time points after drug administration and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours after drug administration, respectively.
Main outcome variables
Drug plasma concentration
General information
Reason for update
Acronym
IRCT registration information
IRCT registration number:IRCT20210519051345N53
Registration date:2024-03-17, 1402/12/27
Registration timing:prospective
Last update:2024-03-17, 1402/12/27
Update count:0
Registration date
2024-03-17, 1402/12/27
Registrant information
Name
Parvin Zakeri-Milani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3334 8801
Email address
pzakeri@tbzmed.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-04-13, 1403/01/25
Expected recruitment end date
2024-10-21, 1403/07/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Fasted-state in vivo bioequivalence study of Diltiazem 60 mg tablet manufactured by MehrDarou compared with innovator product
Public title
Bioequivalence study of Diltiazem 60 mg tablet
Purpose
Other
Inclusion/Exclusion criteria
Inclusion criteria:
General Health (in terms of Liver, Heart and Kidney)
Age (18-59 years)
Exclusion criteria:
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Age
From 18 years old to 59 years old
Gender
Both
Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size:
24
Randomization (investigator's opinion)
Randomized
Randomization description
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Biomedical Research Committe, Tabriz University of Medical Sciences
Street address
No.2 Central Building 3rd Floor, Tabriz University of Medical Sciences, Daneshgah st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Approval date
2024-03-04, 1402/12/14
Ethics committee reference number
IR.TBZMED.REC.1402.1004
Health conditions studied
1
Description of health condition studied
In the present study, the products will be administered to healthy volunteers
ICD-10 code
ICD-10 code description
Primary outcomes
1
Description
Plasma concentration of drug
Timepoint
0.5-12 hours in predetermined time intervals after drug administration
Method of measurement
HPLC (High performance liquid chromatography)
Secondary outcomes
empty
Intervention groups
1
Description
Intervention group: Intervention group will receive a single oral dose of test product (Diltiazem 60 mg tablet manufactured by MehrDarou, Iran) in fasted state. Blood samples will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively
Category
Treatment - Drugs
2
Description
Control group: Control group will receive a single oral dose of reference product (Diltiazem 60 mg tablet manufactured by Sanofi) in fasted state. Blood samples will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.
Category
Treatment - Drugs
Recruitment centers
1
Recruitment center
Name of recruitment center
Faculty of Pharmacy, Tabriz University of Medical Sciences
Full name of responsible person
Parvin Zakeri-Milani
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parviz Shahabi
Street address
No.2 Central Building 3rd Floor, Tabriz University of Medical Science, Daneshgah st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Phone
+98 41 3334 8801
Email
shahabip@tbzmed.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
MehrDarou Pharmaceutical company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry
Person responsible for general inquiries
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Zakeri-Milani
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Zakeri-Milani
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Zakeri-Milani
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Phone
+98 41 3334 8801
Email
pzakeri@tbzmed.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available